Prevention of poxvirus infection by tetrapyrroles

BMC Infectious Diseases

Volumn 3, Issue , 2003, Pages

  Chen Collins, Avril R M ^a   Dixon, Dabney W ^b   Vzorov, Andrei N ^a   Marzilli, Luigi G ^c   Compans, Richard W ^a  

^a EMORY UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10,15,20 TETRAANTHRACEN 9 YL PORPHYRIN; 5,10,15,20 TETRANAPTHALEN 1 YL PORPHYRIN; ANTHRACENYLPORPHYRIN DERIVATIVE; ANTIVIRUS AGENT; CHELATE; COPPER; DEUTEROPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN; HEMATOPORPHYRIN COPPER; MESO(2,6 DIHYDROXYPHENYL)PORPHYRIN; MESOPORPHYRIN; PHTHALOCYANINE DERIVATIVE; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; PROTOPORPHYRIN ZINC; PYRROLE DERIVATIVE; TETRANAPHTHYL; TETRAPHENYLPORPHYRIN DERIVATIVE; TETRAPHENYLPORPHYRIN TETRASULFONATE; TETRASULFOPHTHALOCYANINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHELATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; ELECTRICITY; HALOGENATION; INFECTION PREVENTION; NONHUMAN; POXVIRUS INFECTION; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; SULFONATION; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS STRAIN;

CELL DIVISION; CELL LINE; HELA CELLS; HUMANS; LIGHT; PORPHYRINS; POXVIRIDAE INFECTIONS; PROTOPORPHYRINS; PYRROLES; VACCINIA VIRUS;

EID: 2442664081     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-3-9     Document Type: Article

References (41)

1. Breman JG and Henderson DA: Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism N Engl J Med 1998, 339:556-559.
2. Gani R and Leach S: Transmission potential of smallpox in contemporary populations Nature 2001, 414:748-751.
3. Atlas RM: Bioterriorism: from threat to reality Annu Rev Microbiol 2002, 56:167-85.:167-185.
4. Breman JG and Henderson DA: Diagnosis and management of smallpox N Engl J Med 2002, 346:1300-1308.
5. Sepkowitz KA: How contagious is vaccinia? N Engl J Med 2003, 348:439-446.
6. De Clercq E: Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections Clin Microbiol Rev 2001, 14:382-397.
7. Vzorov AN and Compans RW: Assembly and release of SIV Env proteins with full-length or truncated cytoplasmic domains Virology 1996, 221:22-33.
8. Tobin GJ, Ennis WH, Clanton DJ and Gonda MA: Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay Antiviral Res 1996, 33:21-31.
9. Strober W: Trypan blue exclusion test of cell viability Current Protocols in Immunology Edited by: ColiganJE and KruisbeekAM. New York, Wiley-Greene; 1994:A.3.3-A.3.4.
10. Moss B: Poxviridae: The viruses and their replication Fundamental Virology 3rd edth edition. Edited by: FieldsBN, KnipeDM and HowleyPM. Philadelphia, Lippincott - Raven Press; 1996:1163-1197.
11. Blasco R and Moss B: Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein J Virol 1991, 65:5910-5920.
12. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB and Smith GL: Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope Proc Natl Acad Sci USA 1998, 95:7544-7549.
13. Horowitz B, Williams B, Rywkin S, Prince AM, Pascual D, Geacintov NE and Valinsky J: Inactivation of viruses in blood with aluminum phthalocyanine derivatives Transfusion 1991, 31:102-108.
14. North J, Neyndorff H and Levy JG: Photosensitizers as virucidal agents J Photochem Photobiol B 1993, 17:99-108.
15. Rywkin S, Ben-Hur E, Malik Z, Prince AM, Li Y-S, Kenney ME, Oleinick NL and Horowitz B: New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates Photochem Photobiol 1994, 60:165-170.
16. Smetana Z, Mendelson E, Manor J, van Lier JE, Ben-Hur E, Salzberg S and Malik Z: Photodynamic inactivation of herpes viruses with phthalocyanine derivatives J Photochem Photobiol B 1994, 22:37-43.
17. Margolis-Nunno H, Ben-Hur E, Gottlieb P, Robinson R, Oetjen J and Horowitz B: Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates Transfusion 1996, 36:743-750.
18. Zmudzka BZ, Strickland AG, Beer JZ and Ben-Hur E: Photosensitized decontamination of blood with the silicon phthalocyanine Pc 4: No activation of the human immunodeficiency virus promoter Photochem Photobiol 1997, 65:461-464.
19. Ben-Hur E, Oetjen J and Horowitz B: Silicon phthalocyanine Pc 4 and red light causes apoptosis in HIV-infected cells Photochem Photobiol 1997, 65:456-460.
20. Moor ACE, Wagenaars-van Gompel AE, Hermanns RCA, van der Meulen J, Smit J, Wilschut J, Brand A, Dubbelman TMAR and van Steveninck J: Inhibition of various steps in the replication cycle of vesicular stomatitis virus contributes to its photoinactivation by AlPcS4 or Pc4 and red light Photochem Photobiol 1999, 69:353-359.
21. Gaspard S, Tempete C and Werner GH: Studies on photoinactivation by various phthalocyanines of a free or replicating non-enveloped virus J Photochem Photobiol B 1995, 31:159-162
22. Tsutsui K and Mueller GC: Hemin inhibits virion-associated reverse transcriptase of murine leukemia virus Biochem Biophys Res Commun 1987, 149:628-634.
23. Levere RD, Gong Y-F, Kappas A, Bucher DJ, Wormser GP and Abraham NG: Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine Proc Natl Acad Sci USA 1991, 88:1756-1759.
24. Dixon DW, Kim MS, Kumar V, Obara G, Marzilli LG and Schinazi RF: Amino- and hydroxytetraphenylporphyrins with activity against the human immunodeficiency virus Antiviral Chem Chemother 1992, 3:279-282.
25. Staudinger R, Abraham NG, Levere RD and Kappas A: Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs Proc Assoc Am Physicians 1996, 108:47-54.
26. Argyris EG, Vanderkooi JM and Paterson Y: Mutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme Eur J Biochem 2001, 268:925-931.
27. DeCamp DL, Babé LM, Salto R, Lucich JL, Koo M-S, Kahl SB and Craik CS: Specific inhibition of HIV-1 protease by boronated porphyrins J Med Chem 1992, 35:3426-3428.
28. Song R, Witvrouw M, Schols D, Robert A, Balzarini J, De Clercq E, Bernadou J and Meunier B: Anti-HIV activities of anionic metalloporphyrins and related compounds Antiviral Chem Chemother 1997, 8:85-97.
29. Asanaka M, Kurimura T, Toya H, Ogaki J and Kato Y: Anti-HIV activity of protoporphyrin AIDS 1989, 3:403-404.
30. Dixon DW, Marzilli LG and Schinazi RF: Porphyrins as agents against the human immunodeficiency virus Ann N Y Acad Sci 1990, 616:511-513.
31. Neurath AR, Haberfield P, Joshi B, Hewlett IK, Strick N and Jiang S: Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. I. The V3 loop of gp120 as target. Antiviral Chem Chemother 1991, 2:303-312.
32. Neurath AR, Strick N, Haberfield P and Jiang S: Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120 Antiviral Chem Chemother 1992, 3:55-63.
33. Debnath AK, Jiang S, Strick N, Lin K, Haberfield P and Neurath AR: Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1 J Med Chem 1994, 37:1099-1108.
34. Neurath AR, Strick N and Jiang S: Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. Approaches applicable to epidemic HIV-1 strains Antiviral Chem Chemother 1994, 4:207-214.
35. Neurath AR, Strick N, Lin K, Debnath AK and Jiang S: Tin protoporphyrin-IX used in control of heme metabolism in humans effectively inhibits HIV-1 infection Antiviral Chem Chemother 1994, 5:322-330.
36. Neurath AR, Strick N and Debnath AK: Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency-virus (HIV-1) envelope glycoprotein gp120 J Mol Recognition 1995, 8:345-357.
37. Debnath AK, Jiang SB, Strick N, Lin K, Kahl SB and Neurath AR: Anti-HIV-1 activity of carborane derivatives of porphyrins Med Chem Res 1999, 9:267-275.
38. Vzorov AN, Dixon DW, Trommel JS, Marzilli LG and Compans RW: Inactivation of human immunodeficiency virus type 1 by porphyrins Antimicrob Agents Chemother 2002, 46:3917-3925.
39. De Clercq E: Cidofovir in the treatment of poxvirus infections Antiviral Res 2002, 55:1-13.
40. Smee DF, Sidwell RW, Kefauver D, Bray M and Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses Antimicrob Agents Chemother 2002, 46:1329-1335.
41. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR and Hostetler KY: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir Antimicrob Agents Chemother 2002, 46:991-995.